User fee increase of about 20% under discussion between FDA and industry.
This article was originally published in The Tan Sheet
Executive Summary
FDA/INDUSTRY USER FEE REAUTHORIZATION DISCUSSIONS FOCUSING ON 20% RAISE in user fees as the agency and brand-name pharmaceutical industry seek to reach an agreement in time for the opening of the 105th Congress. FDA is understood to have been seeking roughly a doubling of the fees in exchange for expanded services. The agency, however, could be willing to accept an increase of about 20% to cover a lesser package of commitments on the review process.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning